Author:
Borretta Giorgio,Pia Anna
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference10 articles.
1. Draper N, Stewart PM. 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186: 251, 2005.
2. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth fctors: in vivo and in vitro studies. J Clin Endocrinol Metab 84: 4172, 1999.
3. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metab Disord 3: 255, 2003.
4. Jahn H, Kiefer F, Schick M, Yassouridis A, Steiger A, Kellner M, Wiedemann K. Sleep endocrine effects of the 11-beta-hydroxysteroid dehydrogenase inhibitor metyrapone. Sleep 26: 823, 2003.
5. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, et al. Aryl-sulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11 beta-hydroxysteroid dehydrogenase type 1. J Med Chem 45: 3813, 2002.